Clinical Trial Detail

NCT ID NCT02575339
Title MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Bert O'Neil, MD
Indications

hepatocellular carcinoma

Therapies

Sorafenib

Sapanisertib

Age Groups: adult

No variant requirements are available.